Cleveland Diagnostics, Inc., a commercial-stage precision oncology company, has appointed Valerie Dixon as Chief Financial Officer. She joins with 20 years in healthcare investment banking and strategic finance at a point when the company is building on the commercialisation of its IsoPSA® prostate cancer test and widening the reach of its proprietary IsoClear™ platform.
Dixon comes from Flagship Pioneering, where she was Senior Partner of Financing Services on the Capital Solutions and Value Realization Team. In that role she advised portfolio companies on assessing their financing requirements and shaping strategies for raising external capital.
Her earlier career took in J.P. Morgan, Citigroup and Lehman Brothers, including a spell as an equity research analyst covering medical technology, giving her a close reading of how investors value diagnostics businesses.
She holds an MBA from the Yale School of Management and a Bachelor of Arts in environmental science and public policy from Harvard University.
